The increase of adenylate kinase activity in the blood can control aggregation of platelets in coronary or peripheral arterial ischemia


Activation and aggregation of blood platelets is crucial for hemostasis and thrombosis. In the vascular system adenine nucleotides are important signaling molecules playing a key role in hemostasis. ADP was the first low molecular weight agent recognized to cause blood platelets activation and aggregation. NTPDases and adenylate kinase (AK) are the main enzymes involved in metabolism of extracellular adenine nucleotides. The majority of studies concentrated on the role of NTPDase1 (apyrase) in the inhibition of platelets aggregation. Up to now, there are still insufficient data concerning the role of AK in this process. We found that adenylate kinase activity in the serum of patients with myocardial infarction is significantly increased when compared to the healthy volunteers. The elevated activity of AK is connected to appearance of another isoform of that enzyme, expressed in patients with myocardial infarction. The influence of AK on the pig blood platelets aggregation induced by 20 μM ADP or 7.5 μg/ml rat collagen was examined. 1U of adenylate kinase added to platelet-rich plasma (PRP) before ADP or collagen, inhibited the platelets aggregation. One minute after induction of platelets activation by ADP as much as 5U of adenylate kinase was necessary to stop the platelet aggregation. In the case of collagen activated aggregation, only 2U of AK added 1 or 5 minutes after initiation of the aggregation process were sufficient for disaggregation of platelets. The increase of ATP: ADP ratio is probably responsible for the initiation of disaggregation process. We conclude that adenylate kinase is involved in regulation of plate-lets aggregation. Anticoagulative role of AK indicates the possibility of using this enzyme in the treatment of cardiovascular diseases.

Share and Cite:

Studzińska, B. , Seroka, A. , Lepicka, M. , Roszek, K. and Komoszyński, M. (2010) The increase of adenylate kinase activity in the blood can control aggregation of platelets in coronary or peripheral arterial ischemia. Health, 2, 246-252. doi: 10.4236/health.2010.23035.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Jurk, K. and Kehrel, B.E. (2005) Platelets: Physiology and Biochemistry. Seminars in thrombosis and hemostasis, 31, 381-392.
[2] Willoughby, S., Holmes, A. and Loscalzo, J. (2002) Plate- lets and cardiovascular disease. European Journal of Cardiovascular Nursing, 1, 273-288.
[4] Heptinstall, S., Johnson, A., Glenn, J.R. and White, A.E. (2005) Adenine nucleotide metabolism in human blood– important roles for leukocytes and erythrocytes. Journal of Thrombosis and Haemostasis, 3, 2331-2339.
[5] Cattaneo, M. (2007) Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Review of Cardiovascular Therapy, 5, 45-55.
[6] Erlinge, D. and Burnstock, G. (2008) P2 receptors in cardiovascular regulation and disease. Purinergic Signal, 4, 1-20.
[7] Woulfe, D., Yang, J. and Brass, L. (2001) ADP and platelets: The end of the beginning. Journal of Clinical Investigation, 107, 1591-1598.
[8] Gachet, C. (2001) ADP receptors of platelets and their inhibition. Journal of Thrombosis and Haemostasis, 86, 222-232.
[9] Daniel, J.L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J.B. and Kanapuli, S.P. (1998) Molecular Basis for ADP- induced platelet activation. Journal of Biological Chemistry, 273, 2024-2029.
[10] Kahner , B.N., Shankar, H., Murugappan, S., Prasad, G.L. and Kunapuli, S.P. (2006) Nucleotide receptor signaling in platelets. Journal of Thrombosis and Haemostasis, 4, 2317-2326.
[11] Yegutkin, G.G., Samburski, S.S. and Jalkanen S. (2003) Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counter- acting pyrophosphatase and phosphotransfer reactions. Journal of the Federation of American Societies for Experimental Biology, 17, 1328-1330.
[12] Yegutkin, G.G. (2008) Nucleotide and nucleoside -converting ectoenzymes: Important modulators of puri- nergic signalling cascade. Biochimica et Biophysica Acta, 1783, 673- 694.
[13] Quillen, E.E., Haslam, G.C., Samra, H.S., Amani-Taleshi, D., Knight, J.A., Wyatt, D.E., Bishop, S.C., Colvert, K.K, Richter, M.L. and Kitos, P.A. (2006) Ecto-adenylate kinase and plasma membrane ATP synthase activities of human vascular endothelial cells. Journal of Biological Chemistry, 281, 20728-20737.
[14] Marcus, A.J., Broekman, M.J., Drosopoulos, J.H., Olson, K.E., Islam, N., Pinsky, D.J. and Levi, R. (2005) Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Seminars in Thrombosis and Hemostasis, 31, 234-246.
[15] Atkinson, B., Dwyer, K., Enjyoji, K. and Robson, S.C. (2006) Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells Molecules and Diseases, 36, 217-222.
[16] ??cka, J., Molski, S. and Komoszyński, M. (1999) Alteration of ectopurine metabolism in vascular disease. In Vanduffel L., Lemmens R. (ed.), Ecto-ATPases and related ectonucleotidases. Maastricht, Shaker Publishing BV.
[17] Gellerich, F.N. (1992) The role of adenylate kinase in dynamic compartmentation of adenine nucleotides in the mitochondrial intermembrane space. FEBS Letters, 297, 55-58.
[18] Picher, M. and Boucher, R.C. (2003) Human airway ecto-adenylate kinase. A mechanism to propagate ATP signaling on airway surfaces. Journal of Biological Chemistry, 278, 11256 -11264.
[19] Noma, T. (2005) Dynamics of nucleotide metabolism as a supporter of life phenomena. Journal of Medical Investigation, 52, 127-136.
[20] Haslam, R.J. and Mills, D.C.B. (1967) The adenylate kinase of human plasma, erythrocytes and platelets in relation to the degradation of adenosine diphosphate in plasma. Biochemical Journal, 103, 773-784.
[21] K?drowa, S. and Worsztynowicz-Ja?owiec, E. (1971) Myokinase activity in myocardial infarction. Polish Medical Journal, 10, 805-811.
[22] Frithz, G., Ericsson, P. and Ronquist, G. (1976) Serum adenylate kinase activity in the early phase of acute myocardial infarction. Upsala Journal of Medical Sciences, 81, 155-158.
[23] Rysánek, K., Svehla, C., Spánková, H. and Mlejnková M. (1969) The effect of myokinase on the aggregation and disaggregation of thrombocytes. Experientia, 25, 31-32.
[24] Czarnecka, J., Cie?lak, M. and Komoszyński, M. (2005) Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. Journal of Chromatography B, 822, 85- 90.
[25] Haller, C.A., Cui, W., Wen, J., Robson, S.C. and Chaikof, E.L. (2006) Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. Journal of Vascular Surgery, 43, 816-823.
[26] Yang, M. and Kirley, T.L. (2008) Engineered human sol- uble calcium-activated nucleotidase inhibits coagulation in vitro and thrombosis in vivo. Thrombosis Research, 122, 541-548.
[27] Hamada, M., Sumida, M., Kurokawa Y., Sunayashiki -Kusuzaki, K., Okuda, H., Watanabe, T. and Kuby, S.A. (1984) Studies on the adenylate kinase isozymes from the serum and erythrocyte of normal and Duchenne dystrophic patients. Journal of Biological Chemistry, 260, 11595-11602.
[28] ??cka, J. and Komoszyński, M. (2003) The role of ecto-adenosine and ecto-adenine nucleotides in regulation of blood pressure, haemostasis and etiology of atherosclerosis. Progress in Medical Research, 1, 48-74.
[29] Glaser, P., Presecan, E., Delepierre, M, Surewicz, W.K., Mantsch, H.H., Barzu, O. and Gilles, A.M. (1992) Zinc, a novel structural element found in the family of bacterial adenylate kinases. Biochemistry, 31, 3038-3043.
[30] Furie, B. and Furie, B.C. (2005) Thrombus formation in vivo. Journal of Clinical Investigation, 115, 3355-3362.
[31] Kuwahara, M., Sugimoto, M., Tsuji, S., Matsui, H., Mizuno, T., Miyata, S. and Yoshioka, A. (2002) Platelet shape changes and adhesion under high shear flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 329- 334.
[32] Wan, J., Ristenpart, W.D. and Stone, H.A. (2008) Dynamics of shear-induced ATP release from red blood cell. Proceedings of National Academy of Sciences, USA, 105, 16432-16437.
[33] Kawashima, Y., Nagasawa, T. and Ninomiya, H. (2000) Contribution of ecto-5’-nucleotidase to the inhibition of platelet aggregation by human endothelial cells. Blood, 96, 2157-2162.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.